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Objectives. Analyze the results in terms of local control, survival and toxicity.
Materials and Methods. We performed a retrospective observational study which analyzed data from 31 patients diagnosed with
thymoma and thymic carcinoma between February 1998 and June 2009, according to the classiﬁcation of Masaoka the 38.7%,
29%, 19%, 12.9% were classiﬁed in stage II, III, IVA and IVB respectively, according to the WHO classiﬁcation 3.2%, 21.4%, 21.4%,
3.6%, 10.7% and 39.3% were A, AB, B1, B2, B3 and C respectively.
Results. Of the 31 patients analyzed, 35.5% were male and 64.5% female, with a mean age of 53.5 years (27–74 years). The 35.5%
of patients were diagnosed with thymic carcinoma (operated 45.5%) and 64.5% of patients with thymoma (operated 75%). At
diagnosis, 29% of patients had a paraneoplasic Syndrome, the most frequent myasthenia gravis (66.7%). Unoperated patients
received adjuvant radioterpia with a mean dose of 5940 cGy, with local control of 73.3%. Postoperative patients received a mean
dose of 5040 cGy, with 85% local control. Patients receiving QT were 48.4%, of whom 53.3% were Thymoma and 46.7% thymic
carcinoma, of which 46.7% developed distant metastases With 145 months (12 years) follow-up 55.5% of the patients are alive,
with amedian overall survival of 71months, and a local control in 80%of patients. Of all patients, 87%developed during treatment
acute toxicity, but only 3.22% of patients had G3 pneumonitis and pericarditis.
Conclusions. In our study we obtained a good local control of patients treated with radiotherapy, being higher if associated with
surgery. The toxicity associated with the treatment is generally low grade. Although in our series is not reached statistical
signiﬁcance we have obtained good results in local control.
http://dx.doi.org/10.1016/j.rpor.2013.03.776
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Objectives. In order to implement the No Action Level with Correction Veriﬁcation setup protocol (NAL+COVER) for systematic
error correction in patient positioning, we detail a Monte Carlo simulation developed in Matlab to determine the random error
distribution from a set of off-line measurements of the misalignment of treatment ﬁelds and patient anatomy. This distribution
is needed for the protocol conﬁguration before its clinical implementation. We continue with a detailed description of a practical
way to coordinate treatment sessions with the protocol steps and the deﬁnition of a decision diagram to organize the protocol
execution by the radiotherapy technicians.
Methods. An ofﬂine analysiswas performed at theNALprotocol conﬁguration step on the positioningmisalignments of 36 patients
with radiation therapy treatment in the pelvic region using the Varis Review application of Varian Medical Systems. By means
of a Monte Carlo simulation we achieved the random error distribution for our population.
Results. The width of the random error distribution is 2 mm in all directions and from this value we designed a decision diagram
to implement the protocol and we deﬁned a method to coordinate treatment sessions with the protocol steps. Once the algorithm
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was conﬁgured and used clinically we checked that the number of patients who failed in the COVER step was in agreement with
the statistical simulations so that the proportion of protocol restarts was low.
Conclusions. The NAL+COVER setup protocol proved to be efﬁcient in the minimization of systematic errors in patient positioning,
keeping the additional workload at acceptable values and in good agreement with statistical simulations.
http://dx.doi.org/10.1016/j.rpor.2013.03.777
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Introduction. Total lymphoid irradiation (TLI) impairs the immunologic reaction to allergenic cells, and has been used successfully
to reduce the rate of decline of pulmonary function in patients with evolving or established Bronchiolitis obliterans syndrome
(BOS) despite treatment with immunosuppression regimen.
Objective. To present the single center experience to assess the safety and efﬁcacy of total lymphoid irradiation in controlling
progressive BOS.
Methods. We reviewed patients with BOS after lung transplantation that were treated with TLI at Vall d’Hebron Hospital from
May 2011 to February 2013. Eleven patients were treated with TLI upon treatment failure of drug-based immunosuppression.
Radiation therapy was prescribed as 8 Gy delivered in 10 fractions, 2 fractions/week, in a lineal accelerator with photons of
6–18MV. An AP-PA technique was used with table and collimator rotations to compensate divergencies. Results were assessed
by comparing the highest FEV1 obtained after transplantation and the corresponding BOS classiﬁcation with FEV1 at 3, 6 and 12
months after TLI.
Results. Were analyzed 7 women and 4 men, with a median age of 51.5 years (37–68). The average time between rejection and
TLI was 7.5 months (5–19). BOS classiﬁcation at that time was grade 1, 2 and 3 in 1, 7 and 3 patients respectively. One patient
did not complete the whole treatment due to worsening pulmonary infection. Two patients died, due to BOS progression and
pneumonia, 8 days and 5 months after TLI, respectively. The maximum toxicity reported was gastrointestinal grade 2, accounted
in two patients. The average decrease in FEV1 pre-TLI was 1110cc (580–2150). Pre TLI FEV1 decline was 64.4mls/month, and
27.3mls/month postTLI.
Conclusions. TLI signiﬁcantly reduces the decline rate of FEV1. In our experience, TLI demonstrated important decreased rejection
rates without relevant toxicity.
http://dx.doi.org/10.1016/j.rpor.2013.03.778
Treatment of lumbosacral chordoma with photon-beam radiotherapy
A. Lucas Calduch1, D. León Ordon˜ez2, F. Pino Sorroche3, A. Lozano Borbalás2, M. Nun˜ez Fernández2,
V. Navarro Pérez4, F. Guedea Edo2
1 Institut Català de Oncologia - L’Hospitalet, Radiation Oncology
2 Institut Català d’Oncologia - L’Hospitalet, Radiation Oncology
3 Institut Català d’Oncologia - L’Hospitalet, Medical Physics
4 Institut Català d’Oncologia - L’Hospitalet, Clinical Research Unit
Introduction. Until 5 years ago, patients diagnosed with spinal chordoma were referred to protontherapy centers for treatment.
However, when newer, more advanced technologies became available at our centre, we began using photon-beam therapy to
treat these patients. The availability of high-dose conformal radiotherapy enabled us to manage these patients ourselves. The
present report describes our short term results with this technique.
Objective. To evaluate preliminary results in toxicity and local control in patients treated with photon-beam therapy for spinal
chordoma at our center.
Material. We report on 12 patients with histologically-proven lumbosacral chordoma treated at our center since 2008. The location
of the chordomas was as follows: sacral (7 cases), lumbar (4), and lumbosacral junction (1). All cases were primary except for
one case of multifocal relapse. Previous surgery was complete in 2 patients, subtotal in 4, and partial in 6. Intensity modulated
radiotherapy (IMRT) was used in 11 of the 12 cases (dynamic IMRT in 58% of cases and volumetric IMRT in 33%), with the
exception of one patient that was treated with conformal 3DRT. The mean dose to target volume (PTV1) was 70 Gy. Five patients
received a boost over high risk areas (PTV11), for total mean dose of 78 Gy. Overall survival and local control was obtained using
Kaplan-Meyer estimator.
Results. Treatment was well-tolerated by all patients, with only a single case of grade 3 acute dermatitis. Local control and long-
term toxicity were evaluated in the ﬁrst 9 patients, with a local control rate of 66.7% and overall survival of 100% at two years
after a median follow up of 21 months (range 3–44). Given the limited number of events, it was not possible to identify prognostic
factors. No severe chronic toxicity was observed.
